...
首页> 外文期刊>International Journal of Research in Medical Sciences >Study of microalbuminuria as early risk marker of nephropathy in type 2 diabetic subjects
【24h】

Study of microalbuminuria as early risk marker of nephropathy in type 2 diabetic subjects

机译:微量白蛋白尿作为2型糖尿病患者肾病早期危险指标的研究

获取原文

摘要

Background: Diabetic nephropathy (DN) is a common complication of diabetes mellitus that lead to end-stage of kidney disease (ESKD). Detection of early-stage can slow loss of kidney function and improve patient outcomes with use of diagnostic biomarker detection of DN. Aims and objectives of this study is to evaluate the possible association between glycated hemoglobin and urinary microalbumin as a predictor of diabetic nephropathy in type 2 diabetic patients. Methods: Total 162 subjects were included in this study comprises uncontrolled diabetes 54 cases, controlled diabetes 54 cases and healthy controlled 54 controls. Micro albumin was measured by urinary microalbumin (turbidimetric immunoassay), glycated hemoglobin (HbA1c) measured by ion exchange resin method and fasting blood glucose estimated by GOD-POD method. The inclusion of age group was between 35 to 74 years. Statistical analysis was done by using SPSS, version 16.0. p values were calculated by ANOVA unpaired t-test. The p<0.05 was considered a statistically significant. Results: Urinary microalbumin levels were statistically significant increase in type 2 diabetes mellitus with nephropathy in comparison to uncontrolled diabetes mellitus and controlled diabetes mellitus (138.9±13.7 mg/l vs 67.7±14.1 mg/l and p<0.005**). HbA1c, which acts as a biomarker of diabetes was significant higher diabetic nephropathy, in comparison to uncontrolled diabetes mellitus, controlled diabetes mellitus and healthy control (8.0±1.1% vs 7.1±0.9% and 5.7±0.4%). Conclusions: The present study was demonstrated impaired glycaemic control is associated with elevations in urinary micro albumin levels and it may be considered as risk marker of diabetic nephropathy.
机译:背景:糖尿病肾病(DN)是糖尿病的常见并发症,可导致肾脏疾病(ESKD)的终末期。早期诊断可通过诊断性DN生物标志物检测来减缓肾功能丧失并改善患者预后。这项研究的目的和目的是评估糖化血红蛋白与尿微量白蛋白之间的关联,作为2型糖尿病患者糖尿病肾病的预测指标。方法:本研究共纳入162名受试者,其中包括未控制的糖尿病54例,可控制的糖尿病54例和健康的可控制的54名对照。微量白蛋白通过尿微量白蛋白(比浊免疫法)测定,糖化血红蛋白(HbA1c)通过离子交换树脂法测定,空腹血糖通过GOD-POD法测定。年龄段在35至74岁之间。使用SPSS 16.0版进行统计分析。通过ANOVA不配对t检验计算p值。 p <0.05被认为具有统计学意义。结果:与未控制的糖尿病和可控制的糖尿病相比,患有肾病的2型糖尿病患者的尿微量白蛋白水平在统计学上显着增加(138.9±13.7 mg / l对67.7±14.1 mg / l和p <0.005 **)。与未控制的糖尿病,可控制的糖尿病和健康对照相比,作为糖尿病的生物标志物的HbA1c具有明显更高的糖尿病性肾病(8.0±1.1%vs 7.1±0.9%和5.7±0.4%)。结论:本研究证明血糖控制受损与尿微量白蛋白水平升高有关,可以被认为是糖尿病肾病的危险标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号